Fulcrum's muscle disorder drug fails in late-stage study

Fulcrum Therapeutics

12/09/2024 12:08

Sept 12 (Reuters) - Fulcrum Therapeutics  FULC.O  said
on Thursday its experimental drug to treat a type of genetic
muscle disorder failed to meet the main goal in a late-stage
study.
    Shares of the company slumped over 70% to $2.4 in premarket
trading.

 (Reporting by Bhanvi Satija in Bengaluru; Editing by Vijay
Kishore)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))